Identifying Monoclonal Antibody Mutation Sites Using the Agilent 1290 Infinity II 2D-LC Solution with Q-TOF LC/MS
Applications | 2017 | Agilent TechnologiesInstrumentation
LC/TOF, LC/HRMS, LC/MS, LC/MS/MS, 2D-LC
IndustriesPharma & Biopharma
ManufacturerAgilent Technologies
Key wordsinfliximab, biosimilar, originator, rplc, slslspgk, slslspg, ydywgqgttltvssastk, candidate, nyygstydywgqgttltvssastk, biosimilars, peptide, dimensional, dimension, mutations, heavy, modulation, nyygssydywgqgttltvssastk, nyygst, slslspgi, comparability, monoclonal, first, gradient, flight, scx, two, ado, mabs, solvent, mutation, counts, middle, characterization, antibodies, clone, mapping, antibody, protein, mass, isoforms, assessment, voltage, conjugate, time, chain, maps, spots, biopharmaceuticals, quadrupole, digests
Similar PDF
Analysis of Monoclonal Antibody Digests with the Agilent 1290 Infinity 2D-LC Solution
2017|Agilent Technologies|Applications
Analysis of Monoclonal Antibody Digests with the Agilent 1290 Infinity 2D-LC Solution Application Note Biotherapeutics & Biosimilars Authors Abstract Gerd Vanhoenacker, Koen Sandra, Protein biopharmaceuticals such as monoclonal antibodies and recombinant Isabel Vandenheede, Frank David, and proteins are currently in…
Key words
ter, termodulation, modulationmonoclonal, monoclonalrecombinant, recombinantoxidation, oxidationorthogonality, orthogonalityprotein, proteinstressed, stressedspots, spotsgradient, gradientstress, stresstrastuzumabs, trastuzumabssolvent, solventmethod, methodadyek
Automated Switching between Peptide and Glycan Mapping with the Agilent 1290 Infinity II LC System
2021|Agilent Technologies|Applications
Application Note Biopharma/Pharma Automated Switching between Peptide and Glycan Mapping with the Agilent 1290 Infinity II LC System Increased productivity and flexibility in the characterization of monoclonal antibodies Authors Gerd Vanhoenacker, Aurélie Terrier, Gianni Vandenborre, Pat Sandra, and Koen Sandra…
Key words
glycan, glycanpeptide, peptideoriginator, originatortrastuzumab, trastuzumabmapping, mappingcounts, countsbiosimilar, biosimilaracquisition, acquisitionadvancebio, advancebiounits, unitsresponse, responsefld, fldinstantpc, instantpccho, chorituximab
Analysis of Monoclonal Antibody Digests with the Agilent 1290 Infinity 2D-LC Solution Part 2: HILIC × RPLC-MS
2014|Agilent Technologies|Applications
Analysis of Monoclonal Antibody Digests with the Agilent 1290 Infinity 2D-LC Solution Part 2: HILIC × RPLC-MS Application Note Biotherapeutics & Biosimilars Authors Abstract Gerd Vanhoenacker1, Koen Sandra1,2 , Trastuzumab (marketed as Herceptin), is a monoclonal antibody used in the…
Key words
dimension, dimensionnonstressed, nonstressedsecond, secondtrastuzumab, trastuzumabhilic, hilicter, terrplc, rplcfirst, firstoxidation, oxidationmodulation, modulationflow, flowstressed, stressedhydrophilic, hydrophilicmonoclonal, monoclonalcomprehensive
LC/MS/MS Peptide Mapping Comparison of Innovator and Biosimilars of Rituximab
2019|Agilent Technologies|Applications
Application Note Biotherapeutics and Biosimilars LC/MS/MS Peptide Mapping Comparison of Innovator and Biosimilars of Rituximab Author Suresh Babu C.V. Agilent Technologies, Inc. Abstract The development and manufacturing of biosimilars require comparability studies with innovator biotherapeutic products. This Application Note presents…
Key words
innovator, innovatorpeptide, peptidecounts, countschain, chainmapping, mappingbiosimilar, biosimilarcharge, chargeunmodified, unmodifiedptms, ptmsheavy, heavyassaymap, assaymapbravo, bravottppvldsdgsfflyskl, ttppvldsdgsfflysklmabs, mabsbiosimilars